Results 241 to 250 of about 11,459,182 (339)

ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee, Keyue Chen, Ryan Loke, Xiang Li, David Liubart, Golam T. Saffi, Jonathan T. S. Chow, Ché M. P. Melo, Lydia To, Leonardo Salmena   +9 more
wiley   +1 more source

Gene therapy for hemophilia. [PDF]

Blood Adv
Lenting PJ, Fong S.
europepmc   +1 more source

Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges

Nature reviews. Drug discovery, 2019
M. Cavazzana, F. Bushman, A. Miccio, I. André-Schmutz, E. Six   +4 more
semanticscholar   +1 more source

Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes

Molecular Oncology, EarlyView.
Raphin‐1 reduces the survival of PED‐DHGG cells and enhances their radiation sensitivity through both PeIF2α‐dependent and PeIF2α‐independent mechanisms. Raphin‐1 sustains elevated levels of PeIF2α, contributing to its PeIF2α‐dependent effects. Additionally, raphin‐1 interacts with CReP to mediate a separate radiosensitizing pathway that operates ...
Karin Eytan, Moshe Leitner, Amos Toren, Shoshana Paglin, Michal Yalon   +4 more
wiley   +1 more source

A geminivirus attenuation vector for crop protection using episomal plant gene therapy. [PDF]

Sci Rep
Thompson N, Kandaswamy R, Anwar AF, Polston J, Sunter G, Curtis WR.   +5 more
europepmc   +1 more source

Gene therapy: hopes, hypes, and hurdles.

, 1994
Inder M. Verma
openalex  

TNF-alpha gene therapy for nonimmunogenic tumor using immunogenic variant induced with mutagen (N-methyl-N'-nitro-N-nitrosoguanidine).

, 1996
Eiji Mekata, Nobukuni Terata, Masashi Kodama   +2 more
openalex   +2 more sources

Small modifier, big decision: switching to SUMO mode adds weight to cancer stemness in mammary tumors

Molecular Oncology, EarlyView.
Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley   +1 more source

Harnessing the promises of cell therapy, gene therapy, and regenerative medicine in Québec, Canada. [PDF]

Front Med (Lausanne)
Delisle JS, Fournier D, Santerre K, Rochette S, Zawati MH, Dumont-Lagacé M, Turcotte S, Guertin JR, Vermette P, Tremblay JP, Parisotto M, Beauséjour C, Petropoulos L, Kekre N, Michaud S, Dieudé M.   +15 more
europepmc   +1 more source

GENE THERAPY STRATEGIES OF RESTENOSIS

, 1996
Yasufumi Kaneda, Ryuichi Morishita, Toshio Ogihara   +2 more
openalex   +1 more source